| Year |
Citation |
Score |
| 2023 |
Cohen S, Bambace N, Ahmad I, Roy J, Tang X, Zhang MJ, Burns LJ, Barabé F, Bernard L, Delisle JS, Kiss T, Lachance S, Roy DC, Veilleux O, Sauvageau G. Improved Outcomes of UM171-Expanded Cord Blood Transplantation Compared with Other Graft Sources: Real-World Evidence. Blood Advances. PMID 37467030 DOI: 10.1182/bloodadvances.2023010599 |
0.386 |
|
| 2022 |
Claveau JS, LeBlanc R, Ahmad I, Delisle JS, Cohen S, Kiss T, Bambace NM, Bernard L, Lachance S, Roy DC, Sauvageau G, Veilleux O, Roy J. Bortezomib maintenance after allogeneic transplantation in newly diagnosed myeloma patients results in decreased incidence and severity of chronic GVHD. Transplantation and Cellular Therapy. PMID 36334654 DOI: 10.1016/j.jtct.2022.10.022 |
0.359 |
|
| 2022 |
Lachance S, Bourguignon A, Boisjoly JA, Bouchard P, Ahmad I, Bambace N, Bernard L, Cohen S, Delisle JS, Fleury I, Kiss T, Mollica L, Roy DC, Sauvageau G, Veilleux O, et al. Impact of Implementing a Bendamustine-based Conditioning Regimen on outcomes of Autologous Stem Cell Transplant in Lymphoma while Novel Cellular Therapies Emerge. Transplantation and Cellular Therapy. PMID 36243319 DOI: 10.1016/j.jtct.2022.10.003 |
0.314 |
|
| 2022 |
Kadri Y, Phan M, Bambace N, Bernard L, Cohen S, Delisle JS, Kiss T, Lachance S, Roy DC, Sauvageau G, Veilleux O, Roy J, Ahmad I. Donor Age and Non-Relapse Mortality: Study of Their Association after HLA-Matched Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. Current Oncology (Toronto, Ont.). 29: 5955-5962. PMID 36005208 DOI: 10.3390/curroncol29080470 |
0.362 |
|
| 2021 |
Lachance S, Bourguignon A, Boisjoly J, Ahmad I, Delisle J, Kiss T, Bambace NM, Bernard L, Bouchard P, Cohen S, Roy D, Sauvageau G, Zehr J, Chagnon M, Roy J. Substitution of Carmustine for Bendamustine in the Transplant Conditioning Regimen Improves Survival in Relapsed/Refractory Lymphoma Patients Transplantation and Cellular Therapy. 27: S218. DOI: 10.1016/S2666-6367(21)00269-4 |
0.308 |
|
| 2020 |
Dumont-Lagacé M, Li Q, Tanguay M, Chagraoui J, Kientega T, Cardin GB, Brasey A, Trofimov A, Carli C, Ahmad I, Bambace NM, Bernard L, Kiss TL, Roy J, Roy DC, et al. UM171-expanded cord blood transplants support robust T cell reconstitution with low rates of severe infections. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 33022376 DOI: 10.1016/j.bbmt.2020.09.031 |
0.438 |
|
| 2020 |
LeBlanc R, Claveau JS, Ahmad I, Delisle JS, Bambace N, Bernard L, Cohen S, Kiss T, Lachance S, Landais S, Roy DC, Sauvageau G, Roy J. Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only. Clinical Transplantation. e14099. PMID 32981146 DOI: 10.1111/ctr.14099 |
0.388 |
|
| 2020 |
Haddad K, Potter BJ, Matteau A, Reeves F, Leclerc G, Rivard A, Gobeil F, Roy DC, Noiseux N, Mansour S. Analysis of the COMPARE-AMI trial: First report of long-term safety of CD133+ cells. International Journal of Cardiology. PMID 32553596 DOI: 10.1016/J.Ijcard.2020.06.004 |
0.364 |
|
| 2020 |
Roy DC, Walker I, Maertens J, Lewalle P, Olavarria E, Selleslag D, Lachance S, Buyse M, Wang K, Rovers J, Santi I, Bonig H, Sandler A, Velthuis J, Mielke S. ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia. Leukemia. PMID 32047237 DOI: 10.1038/S41375-020-0733-0 |
0.431 |
|
| 2020 |
Dumont-Lagacé M, Li Q, Tanguay M, Chagraoui J, Kientega T, Cardin G, Brasey A, Trofimov A, Carli C, Ahmad I, Bambace NM, Bernard L, Kiss TL, Roy J, Roy D, et al. UM171-Expanded Cord Blood Transplants Support Robust T-Cell Reconstitution with Low Rates of Severe Infections Blood. 136: 36-37. DOI: 10.1182/blood-2020-139598 |
0.446 |
|
| 2020 |
Cohen S, Roy J, Lachance S, Roy D, Busque L, Barabé F, Ahmad I, Bambace NM, Bernard L, Kiss TL, Sauvageau G. UM171 Expansion Overcomes Shortcomings of Cord Blood Transplantation While Maintaining Benefits Biology of Blood and Marrow Transplantation. 26: S294-S295. DOI: 10.1016/J.Bbmt.2019.12.571 |
0.535 |
|
| 2020 |
Claveau J, LeBlanc R, Ahmad I, Landais S, Bambace NM, Bernard L, Cohen S, Delisle J, Kiss T, Lachance S, Roy D, Sauvageau G, Roy J. Myeloma Patients Relapsing after First Line Treatment with Tandem Auto/Allo Transplant or Auto Transplant Only Have Similar Outcomes. Biology of Blood and Marrow Transplantation. 26: S228-S229. DOI: 10.1016/J.Bbmt.2019.12.469 |
0.49 |
|
| 2020 |
Dumont‐Lagacé M, Li Q, Tanguay M, Chagraoui J, Kientega T, Cardin GB, Brasey A, Trofimov A, Carli C, Ahmad I, Bambace N, Bernard L, Kiss TL, Roy J, Roy D, et al. Single UM171‐Expanded Cord Blood Transplants Support Robust T‐Cell Reconstitution with Low Rates of Severe Infections Stem Cells Translational Medicine. 9. DOI: 10.1002/Sctm.12813 |
0.347 |
|
| 2019 |
Cohen S, Roy J, Lachance S, Delisle JS, Marinier A, Busque L, Roy DC, Barabé F, Ahmad I, Bambace N, Bernard L, Kiss T, Bouchard P, Caudrelier P, Landais S, et al. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study. The Lancet. Haematology. PMID 31704264 DOI: 10.1016/S2352-3026(19)30202-9 |
0.462 |
|
| 2019 |
Dholaria B, Savani BN, Labopin M, Luznik L, Ruggeri A, Mielke S, Al Malki MM, Kongtim P, Fuchs E, Huang XJ, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, ... ... Roy DC, et al. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT. Haematologica. PMID 31537691 DOI: 10.3324/haematol.2019.219790 |
0.378 |
|
| 2019 |
Lemieux C, Ahmad I, Bambace NM, Bernard L, Cohen S, Delisle JS, Fleury I, Kiss T, Mollica L, Roy DC, Sauvageau G, Roy J, Lachance S. Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Lymphoma Patients. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31521818 DOI: 10.1016/J.Bbmt.2019.09.007 |
0.455 |
|
| 2019 |
Roy DC, Lachance S, Cohen S, Delisle JS, Kiss T, Sauvageau G, Busque L, Ahmad I, Bernard L, Bambace N, Boumédine RS, Guertin MC, Rezvani K, Mielke S, Perreault C, et al. Allodepleted T-cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft-versus-host disease (GVHD) in the absence of GVHD prophylaxis. British Journal of Haematology. PMID 31135970 DOI: 10.1111/Bjh.15970 |
0.481 |
|
| 2019 |
Zeidan N, Damen H, Roy DC, Dave VP. Critical Role for TCR Signal Strength and MHC Specificity in ThPOK-Induced CD4 Helper Lineage Choice. Journal of Immunology (Baltimore, Md. : 1950). PMID 31036767 DOI: 10.4049/Jimmunol.1801464 |
0.331 |
|
| 2019 |
Ciurea SO, Al Malki MM, Kongtim P, Fuchs EJ, Luznik L, Huang XJ, Ciceri F, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D, Ben Soussan P, Arnault Y, ... ... Roy DC, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation. PMID 30833742 DOI: 10.1038/S41409-019-0499-Z |
0.359 |
|
| 2019 |
Lemieux C, Ahmad I, Bambace NM, Bernard L, Cohen S, Delisle JS, Fleury I, Kiss T, Mollica L, Roy DC, Sauvageau G, Roy J, Lachance S. Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease. Leukemia Research. PMID 30654975 DOI: 10.1016/J.Leukres.2019.01.002 |
0.482 |
|
| 2019 |
Cohen S, Roy J, Delisle J, Bambace NM, Ahmad I, Lachance S, Bernard L, Barabe F, Kiss TL, Busque L, Roy D, Milano F, Sauvageau G. UM171 Modified Cord Blood Achieves Excellent Survival and Disease Control after 2 Years of Follow-up in High and Very High Risk Malignancies Blood. 134: 3245-3245. DOI: 10.1182/Blood-2019-121698 |
0.502 |
|
| 2019 |
Roy D, Walker I, Maertens J, Lewalle P, Olavarria E, Beguin Y, Selleslag D, Wagner E, Bönig H, Mielke S. A single dose of donor lymphocytes depleted of anti-host reactive T cells (ATIR101) following T-cell-depleted haploidentical HSCT is safe and efficaceous Cytotherapy. 21: S20-S21. DOI: 10.1016/J.JCYT.2019.03.319 |
0.301 |
|
| 2019 |
LeBlanc R, Ahmad I, Terra R, Landais S, Nkoué C, Sebag M, Lemieux-Blanchard É, Bambace N, Bernard L, Cohen S, jean-Sébastien D, Kiss T, Lachance S, Roy D, Sauvageau G, et al. Profound MRD negativity rates after frontline tandem autologous-allogeneic stem cell transplantation followed by bortezomib maintenance in high-risk or young myeloma patients Clinical Lymphoma Myeloma and Leukemia. 19: e41-e42. DOI: 10.1016/J.Clml.2019.09.063 |
0.477 |
|
| 2019 |
Devine SM, Mielke S, Olavarria E, Tuk B, Meewisse K, Sandler A, Roy D. Differential Outcomes for Ex Vivo Versus In Vivo Alloreactive T-Cell Depletion Strategies in Haploidentical HSCT Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.283 |
0.471 |
|
| 2019 |
Roy D, Walker I, Maertens J, Lewalle P, Olavarria E, Beguin Y, Selleslag D, Wagner E, Bönig H, Bos G, Mielke S. A Single Dose of Donor Lymphocytes Depleted of Alloreactive T Cells (ATIR101) after Haploidentical HSCT Is Well-Tolerated and Efficacious: Pooled Analysis of Two Phase II Studies Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.274 |
0.532 |
|
| 2018 |
Hillhouse EE, Thiant S, Moutuou MM, Lombard-Vadnais F, Parat R, Delisle JS, Ahmad I, Roy DC, Guimond M, Roy J, Lesage S. Double negative T cells levels correlate with chronic graft-versus-host disease severity. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30244108 DOI: 10.1016/J.Bbmt.2018.09.008 |
0.516 |
|
| 2018 |
Del'Guidice T, Lepetit-Stoffaes JP, Bordeleau LJ, Roberge J, Théberge V, Lauvaux C, Barbeau X, Trottier J, Dave V, Roy DC, Gaillet B, Garnier A, Guay D. Membrane permeabilizing amphiphilic peptide delivers recombinant transcription factor and CRISPR-Cas9/Cpf1 ribonucleoproteins in hard-to-modify cells. Plos One. 13: e0195558. PMID 29617431 DOI: 10.1371/Journal.Pone.0195558 |
0.329 |
|
| 2018 |
Al Malki M, Jones R, Ma Q, Lee D, Reisner Y, Miller JS, Lang P, Hongeng S, Hari P, Strober S, Yu J, Maziarz R, Mavilio D, Roy DC, Bonini C, et al. Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium - HAPLO2016, San Diego, California, December 1, 2016. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29339270 DOI: 10.1016/J.Bbmt.2018.01.008 |
0.429 |
|
| 2018 |
Ciurea SO, Cao K, Fernadez-Vina M, Kongtim P, Malki MA, Fuchs E, Luznik L, Huang XJ, Ciceri F, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D, ... ... Roy DC, et al. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplantation. PMID 29335625 DOI: 10.1038/s41409-017-0062-8 |
0.343 |
|
| 2018 |
Cohen S, Roy J, Lachance S, Marinier A, Barabé F, Delisle J, Roy D, Busque L, Ahmad I, Bambace NM, Bernard L, Kiss T, Caudrelier P, Larochelle F, Bouchard P, et al. Single UM171 Expanded Cord Blood Transplant is Feasible, Safe, and Permits Transplantation of Better HLA Matched Cords with Very Low Transplant Related Mortality Biology of Blood and Marrow Transplantation. 24: S190-S191. DOI: 10.1182/Blood.V130.Suppl_1.658.658 |
0.397 |
|
| 2018 |
Roy D, Walker I, Maertens J, Lewalle P, Olavarria E, Beguin Y, Selleslag D, Wagner E, Bonig H, Bos G, Mielke S. Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies Blood. 132: 120-120. DOI: 10.1182/Blood-2018-99-119086 |
0.531 |
|
| 2018 |
Devine S, Mielke S, Olavarria E, Tuk B, Meewisse K, Sandler A, Roy D. Depletion of Alloreactive T Cells after Haploidentical HSCT: Comparison of Outcomes for Ex Vivo Versus In Vivo Treatment Strategies Blood. 132: 3474-3474. DOI: 10.1182/Blood-2018-99-118857 |
0.372 |
|
| 2018 |
Leblanc R, Ahmad I, Terra R, Landais S, Nkoue C, Sebag M, Lemieux Blanchard É, Bambace NM, Bernard L, Cohen S, Delisle J, Kiss TL, Lachance S, Roy D, Sauvageau G, et al. Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation Blood. 132: 4666-4666. DOI: 10.1182/Blood-2018-99-112313 |
0.506 |
|
| 2018 |
Cohen S, Roy J, Lachance S, Marinier A, Delisle J, Roy D, Busque L, Ahmad I, Bambace NM, Barabe F, Bernard L, Kiss TL, Bouchard P, Caudrelier P, Larochelle F, et al. Single UM171 Expanded Cord Blood Permits Transplantation of Better HLA Matched Cords with Excellent Gvhd Relapse Free Survival Blood. 132: 4658-4658. DOI: 10.1182/Blood-2018-99-110188 |
0.526 |
|
| 2018 |
Silvestri G, Stramucci L, Ellis J, Harb J, Neviani P, Zhang B, Srutova K, Pineda G, Jamieson C, Calabretta B, Stagno F, Vigneri P, Nteliopoulos G, May P, Reid A, ... ... Roy D, et al. Abstract 1134: The tumor suppressor activity of miR-300 is detrimental for leukemia development but required for leukemia stem cell maintenance Cancer Research. 78: 1134-1134. DOI: 10.1158/1538-7445.Am2018-1134 |
0.305 |
|
| 2018 |
Adassi I, Lebœuf C, Dave V, Roy D. Evaluating the anti-leukemic activity of TH9402-photodepleted PBMCs of allogeneic hematopoietic stem cell transplant patients Cytotherapy. 20: S109-S110. DOI: 10.1016/J.JCYT.2018.02.324 |
0.38 |
|
| 2018 |
Roy D, Walker I, Maertens J, Lewalle P, Olavarria E, Selleslag D, Lachance S, Bönig H, Mielke S. Phase II study of haploidentical stem cell transplantation using ex vivo photodepletion of donor lymphocyte infusions to eliminate anti-host reactivity results in low relapse rates and high survival rates: Final 2 year follow-up Cytotherapy. 20: S10-S11. DOI: 10.1016/J.JCYT.2018.02.016 |
0.344 |
|
| 2018 |
Sarkissian SD, Sauvé J, Larose É, Busque L, Aceros H, Prieto I, Basile F, Stevens L, Mansour S, Roy D, Noiseux N. Differential Expression Analysis Of Cd133+ Stem Cells In Acute And Chronic Mi Patients With Lv Dysfunction Reveals Pathways Associated With Therapeutic Effectiveness Of Stem Cell Therapy For Ischemic Cardiomyopathies Canadian Journal of Cardiology. 34. DOI: 10.1016/J.Cjca.2018.07.195 |
0.316 |
|
| 2018 |
Bouchard P, Brisebois-Boyer A, Charbonneau-Seguin N, Bonhomme V, Ahmad I, Bernard L, Bambace NM, Cohen S, Delisle J, Kiss TL, Sauvageau G, Roy D, Roy J, Lachance S. Effectiveness of Continuous Infusion of Methylprednisolone for Prevention of Antithymocyte Globulin Infusion-Related Reactions in Preparative Regimens for Allogeneic Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 24: S331. DOI: 10.1016/J.Bbmt.2017.12.272 |
0.441 |
|
| 2018 |
Roy J, Ahmad I, Terra R, Landais S, Sebag M, Lemieux-Blanchard É, Bambace NM, Bernard L, Cohen S, Delisle J, Kiss TL, Lachance S, Roy D, Sauvageau G, LeBlanc R. Bortezomib Consolidation after Frontline Auto-Allogeneic Transplant: Low Toxicity and Frequent Immunophenotypic Complete Responses in High-Risk or Young Myeloma Patients Biology of Blood and Marrow Transplantation. 24: S250-S251. DOI: 10.1016/J.Bbmt.2017.12.226 |
0.41 |
|
| 2018 |
Lachance S, Séguin J, Brasey A, Laverdure J, Ho VT, Ritz J, Storek J, Roy D, Busque L, Lemieux S, Perreault C. Prediction of Severe Acute Graft-Versus-Host Disease (GVHD) in Recipients of HLA Identical Hematopoietic Cell Transplantation (HCT) Using Donor Gene Expression Profiling Biology of Blood and Marrow Transplantation. 24: S173-S174. DOI: 10.1016/J.Bbmt.2017.12.123 |
0.436 |
|
| 2018 |
Boisjoly J, Bouchard P, Ahmad I, Bambace NM, Bernard L, Cohen S, Delisle J, Kiss TL, Roy D, Sauvageau G, Roy J, Lachance S. Pharmacoeconomic Impact and Transplant Outcome Associated to Carmustine (BCNU) Substitution with Bendamustine (Be) in the Conditioning Regimen Prior to Autologous Stem Cell Transplantation for Lymphoma Treatment Biology of Blood and Marrow Transplantation. 24: S131-S132. DOI: 10.1016/J.Bbmt.2017.12.074 |
0.457 |
|
| 2017 |
Boisjoly J, Bouchard P, Cohen S, Ahmad I, Bambace NM, Bernard L, Delisle J, Kiss TL, Roy D, Sauvageau G, Roy J, Lachance S. Impact of Carmustine (BCNU) Substitution for Bendamustine in the Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation for the Treatment of Lymphoma Blood. 130: 2022-2022. DOI: 10.1182/Blood.V130.Suppl_1.2022.2022 |
0.431 |
|
| 2017 |
Roy J, Ahmad I, Terra R, Landais S, Sebag M, Lemieux-Blanchard É, Bambace NM, Bernard L, Cohen S, Delisle J, Kiss T, Lachance S, Roy D, Sauvageau G, LeBlanc R. Bortezomib Consolidation after Tandem Auto-Allogeneic Transplantation: High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Newly Diagnosed Myeloma Patients Biology of Blood and Marrow Transplantation. 23: S269-S270. DOI: 10.1016/J.Bbmt.2016.12.435 |
0.403 |
|
| 2016 |
Al Malki MM, Horowitz M, Handgretinger R, Leung W, Roy DC, Huang XJ, Fuchs E, Locatelli F, Blaise D, Mineishi S, Martelli M, Miller J, June C, Ai HS, Luznik L, et al. Proceedings from the Second Haploidentical Stem-cell Transplantation Symposium - Haplo2014, San Francisco, California, December 4, 2014. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26806585 DOI: 10.1016/J.Bbmt.2016.01.001 |
0.353 |
|
| 2016 |
Tardif M, Ahmad I, Bambace NM, Bernard L, Busque L, Delisle J, Kiss T, Fleury I, Lachance S, Mollica L, Nkoué C, Roy D, Roy J, Cohen S. Tandem Autologous Followed By Nonmyeloablative Allogeneic Transplantation in Relapsed High Risk Follicular Lymphoma Leads to Excellent Long Term Progression-Free Survival after 8 Years of Follow-up Blood. 128: 4677-4677. DOI: 10.1182/Blood.V128.22.4677.4677 |
0.415 |
|
| 2016 |
Yu J, Silvestri G, Stramucci L, Sanada M, Yamaguchi T, Du Y, Westermarck J, Caligiuri MA, Garzon R, Milojkovic D, Apperley JF, Roy D, Marcucci G, Calabretta B, Baer MR, et al. Potential Targeting Ph+ Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity Blood. 128: 2909-2909. DOI: 10.1182/Blood.V128.22.2909.2909 |
0.374 |
|
| 2016 |
LeBlanc R, Ahmad I, Terra R, Landais S, Sebag M, Lemieux-Blanchard E, Bambace NM, Bernard L, Cohen S, Delisle J, Kiss T, Lachance S, Roy D, Sauvageau G, Roy J. Bortezomib Consolidation after Nonmyeloablative Allogeneic Stem Cell Transplantation Leads to a High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Multiple Myeloma Patients Blood. 128: 2306-2306. DOI: 10.1182/Blood.V128.22.2306.2306 |
0.429 |
|
| 2016 |
Roy D, Lachance S, Roy J, Walker I, Maertens J, Delisle J, Foley SR, Lewalle P, Olavarria E, Selleslag D, Rüdiger M, Velthuis J, Gerez L, Rovers J, Bonig H, et al. Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL Blood. 128: 1226-1226. DOI: 10.1182/Blood.V128.22.1226.1226 |
0.553 |
|
| 2016 |
Velthuis J, Klar R, Bönig H, Rovers J, Roy D, Prokop L, Stevanovic S, Ruediger M, Krackhardt A. Leukemia-associated Antigen Reactive T-cells in ATIR101, a Recipient-specific Allodepleted T-cell Product to Reduce Relapse Rates and GVHD after Haplo-HSCT Cytotherapy. 18. DOI: 10.1016/J.Jcyt.2016.03.218 |
0.411 |
|
| 2016 |
Hoorn Mvd, Geraedts M, Krackhardt A, Maertens J, Walker I, Bonig H, Roy D, Velthuis J, Ruediger M. Selective Depletion Of Alloreactive T-Cells While Retaining Virus-Specific And Memory T-Cells From Haploidentical Donor Lymphocytes Cytotherapy. 18. DOI: 10.1016/J.Jcyt.2016.03.217 |
0.363 |
|
| 2016 |
Roy D, Lachance S, Roy J, Walker I, Maertens J, Cohen S, Foley R, Lewalle P, Olavarría E, Selleslag D, Ruediger M, Velthuis J, Reitsma K, Gerez L, Rovers J, et al. Phase II Clinical Trial of Allodepleted T Cell Immunotherapy (ATIR101) Post-Transplant Results in Decreased Transplant-Related Mortality and Improved Survival in Acute Leukemia Patients Undergoing T-Depleted Haploidentical Stem Cell Transplantation Cytotherapy. 18. DOI: 10.1016/J.Jcyt.2016.03.040 |
0.503 |
|
| 2016 |
LeBlanc R, Ahmad I, Landais S, Terra R, Bambace NM, Bernard L, Cohen S, Delisle J, Kiss T, Lachance S, Roy D, Sauvageau G, Roy J. Bortezomib Consolidation after Allogeneic Nonmyeloablative Transplantation to Improve Outcome in Poor Prognosis Multiple Myeloma Patients: A Preliminary Safety Report Biology of Blood and Marrow Transplantation. 22: S352-S353. DOI: 10.1016/J.Bbmt.2015.11.848 |
0.391 |
|
| 2015 |
Ahmad I, LeBlanc R, Cohen S, Lachance S, Kiss T, Sauvageau G, Roy DC, Busque L, Delisle JS, Bambace N, Bernard L, Sabry W, Roy J. Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation. Bone Marrow Transplantation. PMID 26691426 DOI: 10.1038/bmt.2015.319 |
0.375 |
|
| 2015 |
Orio J, Carli C, Janelle V, Giroux M, Taillefer J, Goupil M, Richaud M, Roy DC, Delisle JS. Early exposure to interleukin-21 limits rapidly generated anti-Epstein-Barr virus T-cell line differentiation. Cytotherapy. 17: 496-508. PMID 25661862 DOI: 10.1016/J.Jcyt.2014.12.009 |
0.382 |
|
| 2015 |
Silvestri G, Stramucci L, Ellis J, Yu J, Harb J, Neviani P, Marcucci G, Srutova K, Machova Polakova K, Roy D, Hokland P, Deininger MW, Bhatia R, Gambacorti-Passerini C, Milojkovic D, et al. Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML Blood. 126: 53-53. DOI: 10.1182/Blood.V126.23.53.53 |
0.334 |
|
| 2015 |
Thiant S, Moutuou MM, Laflamme P, Boumedine RS, Larochelle F, Leboeuf D, Roy D, Guimond M. Disruption of the Peripheral Lymphoid Niche Contributes to Lymphopenia in CML Patients Undergoing Imatinib Treatments Blood. 126: 5165-5165. DOI: 10.1182/Blood.V126.23.5165.5165 |
0.477 |
|
| 2015 |
Roy D, Lachance S, Roy J, Walker I, Maertens J, Cohen S, Foley SR, Lewalle P, Olavarria E, Selleslag D, Rudiger M, Velthuis J, Reitsma K, Gerez L, Rovers J, et al. Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen Blood. 126: 4391-4391. DOI: 10.1182/Blood.V126.23.4391.4391 |
0.541 |
|
| 2015 |
Thiant S, Roy J, Trottier J, Giard M, Parat R, Roy D, Guimond M. The Impact of Graft-Versus-Host Disease on Dendritic Cell Homeostasis and Their Potential Use As Biomarker to Predict the Severity of Chronic Graft-Versus-Host Disease Blood. 126: 3149-3149. DOI: 10.1182/Blood.V126.23.3149.3149 |
0.469 |
|
| 2015 |
Krakow EF, Bergeron J, Lachance S, Roy D, Delisle J. Phase I Study of Non-Engrafting Allogeneic, Mismatched, Unmanipulated Peripheral Blood Mononuclear Cell Infusions to Treat Poor-Prognosis Acute Myeloid Leukemia Blood. 126: 2562-2562. DOI: 10.1182/Blood.V126.23.2562.2562 |
0.508 |
|
| 2015 |
Noiseux N, Mansour S, Weisel R, Stevens L, Tsang K, Larose E, Li S, Spiller N, Vu M, Crean A, Roy D, Prieto I, Li R, Yau T. THE IMPACT-CABG TRIAL: A CANADIAN RCT OF CD133+ STEM CELL THERAPY FOR ISCHEMIC CARDIOMYOPATHY Canadian Journal of Cardiology. 31: S76. DOI: 10.1016/J.Cjca.2015.07.171 |
0.442 |
|
| 2014 |
Roy DC, Alarco AM, Isasi R. CellCAN: a unique enabler of regenerative medicine and cell therapy in Canada. Stem Cells and Development. 23: 24-8. PMID 25457957 DOI: 10.1089/Scd.2014.0354 |
0.382 |
|
| 2014 |
Fares I, Chagraoui J, Gareau Y, Gingras S, Ruel R, Mayotte N, Csaszar E, Knapp DJ, Miller P, Ngom M, Imren S, Roy DC, Watts KL, Kiem HP, Herrington R, et al. Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science (New York, N.Y.). 345: 1509-12. PMID 25237102 DOI: 10.1126/Science.1256337 |
0.324 |
|
| 2014 |
Krakow EF, Bergeron J, Lachance S, Roy DC, Delisle JS. Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment. Blood Reviews. 28: 249-61. PMID 25228333 DOI: 10.1016/J.Blre.2014.08.002 |
0.485 |
|
| 2014 |
Dumont N, Boyer L, Émond H, Celebi-Saltik B, Pasha R, Bazin R, Mantovani D, Roy DC, Pineault N. Medium conditioned with mesenchymal stromal cell-derived osteoblasts improves the expansion and engraftment properties of cord blood progenitors. Experimental Hematology. 42: 741-52.e1. PMID 24793546 DOI: 10.1016/J.Exphem.2014.04.009 |
0.428 |
|
| 2014 |
Fournier M, Savoie-Rondeau I, Larochelle F, Hassawi M, Shestakova EA, Roy DC, Bijl JJ. Inability of HOXB4 to enhance self-renewal of malignant B cells: favorable profile for the expansion of autologous hematopoietic stem cells. Experimental Hematology. 42: 526-35.e4. PMID 24503485 DOI: 10.1016/J.Exphem.2014.01.011 |
0.348 |
|
| 2014 |
Ogbogu U, Burningham S, Ollenberger A, Calder K, Du L, El Emam K, Hyde-Lay R, Isasi R, Joly Y, Kerr I, Malin B, McDonald M, Penney S, Piat G, Roy DC, et al. Policy recommendations for addressing privacy challenges associated with cell-based research and interventions. Bmc Medical Ethics. 15: 7. PMID 24485220 DOI: 10.1186/1472-6939-15-7 |
0.319 |
|
| 2014 |
Silvestri G, Ellis J, Stramucci L, Harb JG, Neviani P, Marcucci G, Roy D, Hokland P, Milojkovic D, Reid A, Apperley JF, Livak FM, Baer MR, Trotta R, Perrotti D. MiR-300 Acts As a Tumor Supressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/β-Catenin Interplay Blood. 124: 4529-4529. DOI: 10.1182/Blood.V124.21.4529.4529 |
0.351 |
|
| 2014 |
Roy D, Maertens J, Walker I, Lachance S, Roy J, Foley SR, Lewalle P, Selleslag DL, De Jong L, Velthuis JH, Gerez L, Reitsma K, Wagena E, Mielke S. Selective Photodepletion of Recipient-Alloreactive T-Cells Enables Safe and Efficacious Haploidentical HSCT: Initial Results from a Phase 2 Trial in Patients with AML, ALL, and MDS Blood. 124: 314-314. DOI: 10.1182/Blood.V124.21.314.314 |
0.535 |
|
| 2014 |
Velthuis JHL, Jong LD, Boumédine RS, Giard M, Roy D, Rüdiger M. Selective Depletion of Recipient-Alloreactive T-Cells While Retaining Viral-Specific and Memory T-Cells Enables Safe and Efficacious Haplo-Identical HSCT Blood. 124: 2490-2490. DOI: 10.1182/Blood.V124.21.2490.2490 |
0.462 |
|
| 2014 |
Bastien J, Dave V, Cournoyer É, Roy D. Cellular therapy using TH9402 for the expansion of Tregs in the treatment of chronic graft versus host disease Cytotherapy. 16. DOI: 10.1016/J.Jcyt.2014.01.097 |
0.323 |
|
| 2014 |
Roy D, Maertens J, Walker I, Foley R, Lewalle P, Selleslag D, Velthuis J, Gerez L, Reitsma K, Wagena E, Roy J, Lachance S, Mielke S. Immunotherapy with donor lymphocytes depleted of anti-host reactive cells results in safe and efficacious haploidentical HSCT: interim results from a phase II trial in patients with hematologic malignancies Cytotherapy. 16. DOI: 10.1016/J.Jcyt.2014.01.085 |
0.341 |
|
| 2014 |
Jong Ld, Velthuis J, Darwiche J, Corrieveau M, Ruediger M, Preti R, Roy D. Standardization and characterization of ATIR cell therapy product: applying QbD to both process and assay development Cytotherapy. 16. DOI: 10.1016/J.Jcyt.2014.01.073 |
0.384 |
|
| 2014 |
Velthuis J, Jong LD, Boumédine RS, Giard M, Roy D, Ruediger M. Selective depletion of recipient-alloreactive T-cells while retaining viral-specific and memory T-cells enables safe and efficacious haplo-identical HSCT Cytotherapy. 16. DOI: 10.1016/J.Jcyt.2014.01.058 |
0.378 |
|
| 2014 |
Laflamme V, Trottier J, Pineault N, Vibhuti D, Roy D. Declined Presentation: Megakaryocyte progenitors capable of producing functional platelets can be expanded ex vivo from CD34+ hematopoietic stem/progenitor cells Experimental Hematology. 42. DOI: 10.1016/J.Exphem.2014.07.162 |
0.4 |
|
| 2014 |
Roy D. Functional T-cells without alloreactivity Experimental Hematology. 42. DOI: 10.1016/J.Exphem.2014.07.011 |
0.338 |
|
| 2014 |
Vu M, DerSarkissian S, Stevens L, Mansour S, Borie M, Roy D, Noiseux N. Preconditioning Human Stem Cells With Oxytocin To Optimize Cell Therapy For The Treatment Of Cardiovascular Disease Canadian Journal of Cardiology. 30. DOI: 10.1016/J.Cjca.2014.07.020 |
0.466 |
|
| 2013 |
Manuguerra-Gagné R, Boulos PR, Ammar A, Leblond FA, Krosl G, Pichette V, Lesk MR, Roy DC. Transplantation of mesenchymal stem cells promotes tissue regeneration in a glaucoma model through laser-induced paracrine factor secretion and progenitor cell recruitment. Stem Cells (Dayton, Ohio). 31: 1136-48. PMID 23495088 DOI: 10.1002/Stem.1364 |
0.405 |
|
| 2013 |
Forcillo J, Stevens LM, Mansour S, Prieto I, Salem R, Baron C, Roy DC, Larose E, Masckauchan D, Noiseux N. Implantation of CD133+ stem cells in patients undergoing coronary bypass surgery: IMPACT-CABG pilot trial. The Canadian Journal of Cardiology. 29: 441-7. PMID 23265095 DOI: 10.1016/J.Cjca.2012.08.009 |
0.404 |
|
| 2013 |
Ahmad I, Cohen S, Lachance S, Sauvageau G, Roy D, Busque L, Kiss T, Delisle J, Bernard L, LeBlanc R, Roy J. Pre-Transplant Remission Status and Peripheral Blood Stem Cell Graft Contribute To Long-Term Outcome After Myeloablative Sibling-Donor Allogeneic Transplant For Multiple Myeloma Blood. 122: 5541-5541. DOI: 10.1182/Blood.V122.21.5541.5541 |
0.498 |
|
| 2013 |
Ahmad I, Cohen S, Lachance S, Sauvageau G, Kiss T, Busque L, Roy D, Delisle J, Bernard L, LeBlanc R, Roy J. High Progression-Free Survival At 10 Years After Tandem Autologous/Nonmyeloablative Allogeneic Transplants For Multiple Myeloma In a Cohort Of 93 Patients: Impact Of Disease Remission Status At Transplant and Chronic Graft-Versus-Host Disease Blood. 122: 3353-3353. DOI: 10.1182/Blood.V122.21.3353.3353 |
0.465 |
|
| 2013 |
Guenda K, Roy J, Ahmad I, Bernard L, Cohen S, Delisle J, Kiss T, Roy D, Sauvageau G, Chagnon M, Lachance S. Pneumatosis Coli Associated to Severe Intestinal Graft Versus Host Disease Following Hematopoietic Cell Transplantation: Risk Factors and Dismal Outcome Biology of Blood and Marrow Transplantation. 19: S333. DOI: 10.1016/J.Bbmt.2012.11.506 |
0.428 |
|
| 2013 |
Bambace NM, Poirier L, Cohen S, Kiss T, Sauvageau G, Roy J, Roy D, Chagnon M, Lachance S. Nocardiosis in Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Matched Case-Control Study of Risk Factors, Clinical Features and Outcomes Biology of Blood and Marrow Transplantation. 19: S280. DOI: 10.1016/J.Bbmt.2012.11.396 |
0.447 |
|
| 2013 |
Bourgouin P, Krakow EF, Roy J, Ahmad I, Bernard L, Delisle J, Kiss T, Lachance S, Roy D, Sauvageau G, Cohen S. Prompt Treatment of Respiratory Syncytial Virus with Inhaled Ribavirin and IVIG in High Risk Allogeneic Stem Cell Transplant Recipients Significantly Diminishes Mortality Biology of Blood and Marrow Transplantation. 19: S258-S259. DOI: 10.1016/J.Bbmt.2012.11.347 |
0.432 |
|
| 2012 |
Bastien JP, Roy J, Roy DC. Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation. Seminars in Oncology. 39: 674-82. PMID 23206844 DOI: 10.1053/J.Seminoncol.2012.09.004 |
0.417 |
|
| 2012 |
Noiseux N, Borie M, Desnoyers A, Menaouar A, Stevens LM, Mansour S, Danalache BA, Roy DC, Jankowski M, Gutkowska J. Preconditioning of stem cells by oxytocin to improve their therapeutic potential. Endocrinology. 153: 5361-72. PMID 23024264 DOI: 10.1210/En.2012-1402 |
0.375 |
|
| 2012 |
Émond H, Boyer L, Roy DC, Pineault N. Cotransplantation of ex vivo expanded progenitors with nonexpanded cord blood cells improves platelet recovery. Stem Cells and Development. 21: 3209-19. PMID 22783996 DOI: 10.1089/Scd.2012.0142 |
0.465 |
|
| 2012 |
Cheung AM, Leung D, Rostamirad S, Dhillon K, Miller PH, Droumeva R, Brinkman RR, Hogge D, Roy DC, Eaves CJ. Distinct but phenotypically heterogeneous human cell populations produce rapid recovery of platelets and neutrophils after transplantation. Blood. 119: 3431-9. PMID 22374695 DOI: 10.1182/Blood-2011-12-398024 |
0.407 |
|
| 2012 |
Cohen S, Kiss T, Lachance S, Roy DC, Sauvageau G, Busque L, Ahmad I, Roy J. Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 18: 951-7. PMID 22155507 DOI: 10.1182/Blood.V114.22.50.50 |
0.489 |
|
| 2012 |
Holbro A, Ahmad I, Busque L, Cohen S, Lachance S, Roy DC, Roy J, Sauvageau G, Kiss T. Cardiac tamponade potentially related to sirolimus following cord blood transplantation. Bone Marrow Transplantation. 47: 294-5. PMID 21399672 DOI: 10.1038/Bmt.2011.44 |
0.336 |
|
| 2012 |
Noiseux N, Borie M, Desnoyers A, Menaouar A, Stevens L, Mansour S, Danalache BA, Roy D, Jankowski M, Gutkowska J. 531 Improving Stem Cell Therapeutic Potential by Oxytocin Preconditioning Canadian Journal of Cardiology. 28. DOI: 10.1016/J.Cjca.2012.07.484 |
0.38 |
|
| 2012 |
Pécheux L, Ahmad I, Baron C, Busque L, Cohen S, Kiss T, Roy D, Roy J, Sauvageau G, Lachance S. Impact of Graft CD34 Cell Dose on Chronic Graft-Versus-Host Disease (cGVHD) and Predictive Values of CD3 Cell Dose and Day 56 Chimerism on Survival in Nonmyeloablative (Nma) Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Biology of Blood and Marrow Transplantation. 18: S262-S263. DOI: 10.1016/J.Bbmt.2011.12.173 |
0.404 |
|
| 2011 |
Forcillo J, Stevens LM, Mansour S, Prieto I, Roy DC, Noiseux N. IMPACT-CABG Trial: Implantation of CD133(+) Stem Cells in Patients Undergoing Coronary Bypass Surgery-Presentation of the First Treated Patient. Case Reports in Transplantation. 2011: 685394. PMID 23213603 DOI: 10.1155/2011/685394 |
0.382 |
|
| 2011 |
Mansour S, Roy DC, Bouchard V, Stevens LM, Gobeil F, Rivard A, Leclerc G, Reeves F, Noiseux N. One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133 Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction. Bone Marrow Research. 2011: 385124. PMID 22046562 DOI: 10.1155/2011/385124 |
0.401 |
|
| 2011 |
Vincent K, Roy DC, Perreault C. Next-generation leukemia immunotherapy. Blood. 118: 2951-9. PMID 21734234 DOI: 10.1182/Blood-2011-04-350868 |
0.463 |
|
| 2011 |
Ahmad I, Labbé AC, Chagnon M, Busque L, Cohen S, Kiss T, Lachance S, Roy DC, Sauvageau G, Roy J. Incidence and prognostic value of eosinophilia in chronic graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 17: 1673-8. PMID 21601640 DOI: 10.1016/J.Bbmt.2011.04.012 |
0.493 |
|
| 2011 |
Pineault N, Cortin V, Boyer L, Garnier A, Robert A, Thérien C, Roy DC. Individual and synergistic cytokine effects controlling the expansion of cord blood CD34(+) cells and megakaryocyte progenitors in culture. Cytotherapy. 13: 467-80. PMID 21090916 DOI: 10.3109/14653249.2010.530651 |
0.454 |
|
| 2011 |
Delage R, Turner AR, Leber B, Hasegawa WS, Roy D, Savoie ML, Leitch HA, Bence-Bruckler I, Forrest DL, Kanjeekal S, Sandeep S, Laneuville P, Assouline S, Grewal K, Kovacs MJ, et al. A Canadian Expanded Access Trial of Oral Nilotinb in Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Blood. 118: 4437-4437. DOI: 10.1182/Blood.V118.21.4437.4437 |
0.351 |
|
| 2011 |
Roy D, Guerin M, Boumedine RS, Lachance S, Cohen S, Sauvageau G, Kiss T, Busque L, Morin J, Guertin M, Velardi A, Rezvani K, Mielke S, Egeler RM, Barrett AJ, et al. Reduction in Incidence of Severe Infections by Transplantation of High Doses of Haploidentical T Cells Selectively Depleted of Alloreactive Units Blood. 118: 3020-3020. DOI: 10.1182/Blood.V118.21.3020.3020 |
0.546 |
|
| 2011 |
Fares IH, Chagraoui J, Krosl J, Roy D, Cohen S, Sauvageau G. Screen for Small Molecules Capable of Expanding Human Hematopoietic Stem Cell Ex Vivo Blood. 118: 1919-1919. DOI: 10.1182/Blood.V118.21.1919.1919 |
0.432 |
|
| 2011 |
Neviani P, Harb J, Oaks J, Walker C, Santhanam R, Paisie C, Eiring A, Zhang B, Perazzona B, Ma Y, Mao C, Marcucci G, Holyoake T, Volinia S, Cortes J, ... ... Roy D, et al. Abstract LB-109: BCR-ABL1 kinase activity but not its expression is dispensable for Ph+ quiescent stem cell survival which depends on the PP2A-controlled Jak2 activation and is sensitive to FTY720 treatment Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-109 |
0.393 |
|
| 2011 |
Baron C, Ahmad I, Busque L, Cohen S, Depeault L, Lachance S, Roy D, Roy J, Sauvageau G, Kiss T. The Number of CD34+ Cells in Peripheral Blood Pre Leukapheresis of Allogeneic Stem Cell Donors is Related to Donor Demographic and Hematologic Factors on the Day of Collection. Results of a Single Center Stem Cell Collection Validation Study Biology of Blood and Marrow Transplantation. 17: S306. DOI: 10.1016/J.Bbmt.2010.12.455 |
0.376 |
|
| 2010 |
Bastien JP, Krosl G, Therien C, Rashkovan M, Scotto C, Cohen S, Allan DS, Hogge D, Egeler RM, Perreault C, Roy DC. Photodepletion differentially affects CD4+ Tregs versus CD4+ effector T cells from patients with chronic graft-versus-host disease. Blood. 116: 4859-69. PMID 20798236 DOI: 10.1182/Blood-2010-03-273193 |
0.375 |
|
| 2010 |
Mansour S, Roy DC, Bouchard V, Nguyen BK, Stevens LM, Gobeil F, Rivard A, Leclerc G, Reeves F, Noiseux N. COMPARE-AMI trial: comparison of intracoronary injection of CD133+ bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction: study rationale and design. Journal of Cardiovascular Translational Research. 3: 153-9. PMID 20560029 DOI: 10.1007/S12265-009-9145-2 |
0.405 |
|
| 2010 |
Neviani P, Harb JG, Oaks JJ, Walker C, Santhanam R, Paisie C, Eiring A, Zhang B, Perazzona B, Ma Y, Mao C, Marcucci G, Holyoake TL, Volinia S, Cortes JE, ... ... Roy D, et al. BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment Blood. 116: 515-515. DOI: 10.1182/Blood.V116.21.515.515 |
0.448 |
|
| 2010 |
Bastien J, Krosl G, Therien C, Rashkovan M, Scotto C, Cohen S, Allan DS, Hogge DE, Egeler RM, Perreault C, Roy D. Novel Photodepletion Strategy to Preserve and Expand Tregs While Eliminating CD4+ Effector T Cells From Patients with Chronic Graft-Versus-Host Disease Blood. 116: 353-353. DOI: 10.1182/Blood.V116.21.353.353 |
0.466 |
|
| 2010 |
Harb JG, Neviani P, Oaks JJ, Marcucci G, Hokland P, Roy D, Perrotti D. The BCR-ABL1-Regulated hnRNP A1, hnRNP E2, and hnRNP K Are Differentially Expressed Between CD34+ and CD34+/CD38- Ph+ Cells, and After Blastic Transformation of CML. Blood. 116: 1222-1222. DOI: 10.1182/Blood.V116.21.1222.1222 |
0.361 |
|
| 2009 |
Mansour S, Roy DC, Lemieux B, Ouellet C, Stevens LM, Noiseux N. Stem cell therapy for the broken heart: mini-organ transplantation. Transplantation Proceedings. 41: 3353-7. PMID 19857748 DOI: 10.1016/j.transproceed.2009.08.033 |
0.326 |
|
| 2009 |
Sabry W, Le Blanc R, Labbé AC, Sauvageau G, Couban S, Kiss T, Busque L, Cohen S, Lachance S, Roy DC, Roy J. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 15: 919-29. PMID 19589481 DOI: 10.1016/J.Bbmt.2009.04.004 |
0.461 |
|
| 2009 |
Mollica L, Fleury I, Belisle C, Provost S, Roy DC, Busque L. No association between telomere length and blood cell counts in elderly individuals. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. 64: 965-7. PMID 19435952 DOI: 10.1093/Gerona/Glp065 |
0.374 |
|
| 2009 |
Roy D, Lachance S, Kiss T, Cohen S, Busque L, Fish D, Sauvageau G, Egeler M, Roy J. Haploidentical Stem Cell Transplantation: High Doses of Alloreactive-T Cell Depleted Donor Lymphocytes Administered Post-Transplant Decrease Infections and Improve Survival without Causing Severe Gvhd. Blood. 114: 512-512. DOI: 10.1182/Blood.V114.22.512.512 |
0.548 |
|
| 2009 |
Lachance S, Molucon-Chabrot C, Busque L, Kiss T, Cohen S, Roy D, Roy J, Sauvageau G. First Line Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma (MCL). Blood. 114: 3366-3366. DOI: 10.1182/Blood.V114.22.3366.3366 |
0.468 |
|
| 2009 |
Oaks J, Neviani P, Mukhopadhyay A, Santhanam R, Ma Y, Mao C, Marcucci G, Chen C, Cortes J, Caligiuri MA, Hokland P, Huettner C, Koschmieder S, Cancelas J, Briesewitz R, ... ... Roy D, et al. FTY720 but Not Its Immunosuppressive Phosphorylated Form FTY720-P Exerts Anti-Leukemic Activity towards Ph(+) and Ph(−) Myeloproliferative Disorders through Reactivation of the PP2A Tumor Suppressor. Blood. 114: 3259-3259. DOI: 10.1182/Blood.V114.22.3259.3259 |
0.358 |
|
| 2009 |
Assouline SE, Cocolakis E, Rousseau C, Culjkovic B, Beslu N, Amri A, Caplan SN, Leber B, Roy D, Borden KLB, Miller WH. Targeting the Oncogene eIF4E with Ribavirin: A Novel Therapeutic Avenue in Acute Myeloid Leukemia. Blood. 114: 2085-2085. DOI: 10.1182/Blood.V114.22.2085.2085 |
0.374 |
|
| 2009 |
Ahmad I, Boutin M, Thibault P, Busque L, Cohen S, Kiss T, Lachance S, Roy D, Sauvageau G, Roy J. Collagen and Elastin Degradation Products as Potential Biomarkers for Chronic Graft-Versus-Host Disease (cGVHD). Blood. 114: 1156-1156. DOI: 10.1182/Blood.V114.22.1156.1156 |
0.39 |
|
| 2009 |
Detrait M, Boivin G, Delage R, Béliveau C, Labbé A, Cohen S, Kiss T, Busque L, Roy D, Sauvageau G, Roy J. High Dose Valacyclovir Is Highly Effective to Prevent Cytomegalovirus and Other Herpes Viruses Viremia After Allogeneic Stem Cell Transplantation. Blood. 114: 1140-1140. DOI: 10.1182/Blood.V114.22.1140.1140 |
0.473 |
|
| 2009 |
Roy D, Cohen S, Busque L, Fish D, Kiss T, Lachance S, Sauvageau G, Rovers J, Roy J. Donor Lymphocyte Infusions Depleted of Alloreactive T Cells Decrease Infections without Causing GVHD After Haplotype Mismatched Myeloablative Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 15: 19. DOI: 10.1016/J.Bbmt.2008.12.057 |
0.401 |
|
| 2008 |
Sabry W, Fontaine A, Le Blanc R, Sauvageau G, Roy D, Busque L, Cohen S, Kiss T, Lachance S, Roy J. Tandem Autologous-Nonmyeloablative (NMA) Allogeneic(Allo) Transplant (Tx) in Newly Diagnosed Multiple Myeloma (MM) Leads to Improved Survival When Compared to Conventional Allogeneic Transplant Blood. 112: 3299-3299. DOI: 10.1182/Blood.V112.11.3299.3299 |
0.467 |
|
| 2008 |
Neviani P, Santhanam R, Ma Y, Marcucci G, Byrd JC, Chen C, Cortes J, Caligiuri MA, Huettner C, Bhatia R, Roy D, Perrotti D. Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34+/CD38− Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL– independent Signals Blood. 112: 189-189. DOI: 10.1182/Blood.V112.11.189.189 |
0.467 |
|
| 2008 |
Sabry W, Labbé A, Le Blanc R, Sauvageau G, Roy D, Busque L, Cohen S, Kiss T, Lachance S, Roy J. Graft-Versus-Host Disease (Gvhd) Prophylaxis with Tacrolimus and Mycophenolate Mofetil (MMF) in 131 Matched Sibling Nonmyeloablative (NMA) Transplant Recipients: Long-Term Follow-up Confirms Extremely Low Incidence of Acute (a) Gvhd, High Incidence of Extensive Chronic (c) Gvhd and Favorable Disease Outcome. Blood. 112: 1176-1176. DOI: 10.1182/Blood.V112.11.1176.1176 |
0.441 |
|
| 2007 |
Labbé AC, Su SH, Laverdière M, Pépin J, Patiño C, Cohen S, Kiss T, Lachance S, Sauvageau G, Busque L, Roy DC, Roy J. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 13: 1192-200. PMID 17889356 DOI: 10.1016/J.Bbmt.2007.06.013 |
0.454 |
|
| 2007 |
Allan DS, Dubé P, Roy J, Busque L, Roy DC. Endothelial-like vascular progenitor cells (VPCs) from allogeneic and autologous donors: mobilization features distinct from hematopoietic progenitors. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 13: 433-9. PMID 17382249 DOI: 10.1016/J.Bbmt.2006.11.016 |
0.397 |
|
| 2007 |
Baron C, Somogyi R, Greller LD, Rineau V, Wilkinson P, Cho CR, Cameron MJ, Kelvin DJ, Chagnon P, Roy DC, Busque L, Sékaly RP, Perreault C. Prediction of graft-versus-host disease in humans by donor gene-expression profiling. Plos Medicine. 4: e23. PMID 17378698 DOI: 10.1371/Journal.Pmed.0040023 |
0.444 |
|
| 2007 |
Bastien J, Krosl G, Dube P, Therien C, Scotto C, Roy D. Anti-Chronic Graft Versus Host Disease Activity Though a Regulatory T Cell Dependent Mechanism after Photodynamic Therapy. Blood. 110: 3280-3280. DOI: 10.1182/Blood.V110.11.3280.3280 |
0.471 |
|
| 2007 |
Roy D, Cohen S, Busque L, Fish D, Kiss T, Lachance S, Sauvageau G, Caudrelier P, Roy J. Phase I Clinical Trial of Haplotype Mismatched Myeloablative Stem Cell Transplantation: Higher Doses of Donor Lymphocyte Infusions Depleted of Alloreactive Cells Using ATIR May Improve Outcome without Causing GVHD. Blood. 110: 2976-2976. DOI: 10.1182/Blood.V110.11.2976.2976 |
0.563 |
|
| 2007 |
Gagnon L, Barabe J, Penney C, Roy D, Kovcin V, Bosnjak S, Laurin P. Oral Treatment with PBI-1402 Increases Hemoglobin Level and Red Blood Cell Count: A Novel Approach to Treating Chemotherapy-Induced Anemia. Blood. 110: 2211-2211. DOI: 10.1182/Blood.V110.11.2211.2211 |
0.362 |
|
| 2007 |
Bouchard P, Bilodeau S, Alain K, Vadnais B, Franco M, Busque L, Roy D, Pronovost B, Michaud V, BPharm JT. Assessment of Individual Characteristics on the Pharmacokinetics of Oral Busulfan in Adults Patients Undergoing Hematopoietic Stem-Cell Transplantation. Blood. 110: 1993-1993. DOI: 10.1182/Blood.V110.11.1993.1993 |
0.316 |
|
| 2007 |
Bijl JJ, Cherief H, Roy D. Deletion of HoxA Genes Inhibits Proliferation and Differentiation of Myeloid Progenitors. Blood. 110: 1271-1271. DOI: 10.1182/Blood.V110.11.1271.1271 |
0.356 |
|
| 2007 |
Roy D, Cohen S, Busque L, Fish D, Kiss T, Lachance S, Sauvageau G, Caudrelier P, Roy J. 49: Haplotype mismatched myeloablative stem cell transplantation Biology of Blood and Marrow Transplantation. 13: 20-21. DOI: 10.1016/J.Bbmt.2006.12.052 |
0.37 |
|
| 2006 |
Kelly M, Roy DC, Labbe AC, Laverdiere M. What is the clinical significance of infusing hematopoietic cell grafts contaminated with bacteria? Bone Marrow Transplantation. 38: 183-188. PMID 16785868 DOI: 10.1038/sj.bmt.1705421 |
0.307 |
|
| 2006 |
Dhédin N, Chamakhi I, Perreault C, Roy DC, Sauvageau G, Ducruet T, Busque L, Fish D, Bélanger R, Roy J. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation. Experimental Hematology. 34: 107-14. PMID 16413397 DOI: 10.1016/J.Exphem.2005.09.013 |
0.497 |
|
| 2006 |
Laneuville P, Barnett MJ, Belanger R, Couban S, Forrest DL, Roy D, Lipton JH. Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia Current Oncology. 13: 201-221. DOI: 10.3747/Co.V13I6.124 |
0.355 |
|
| 2006 |
Lagraoui M, Grouix B, Julien N, Asselin M, Gaudreau D, Sarra-Bournet F, Morin M, Krosl G, Roy D, Penney C, Gagnon L. PBI-1402: A Non-Toxic Immunorestorative Small Molecule for the Treatment of Anemia. Blood. 108: 4224-4224. DOI: 10.1182/Blood.V108.11.4224.4224 |
0.421 |
|
| 2006 |
Gagnon L, Barabé J, Lagraoui M, Grouix B, Julien N, Asselin M, Gaudreau D, Sarra-Bournet F, Zacharie B, Penney C, Laurin P, Morin M, Krosl G, Roy D. PBI-1402: A New Candidate for the Treatment of Anemia. Blood. 108: 4223-4223. DOI: 10.1182/Blood.V108.11.4223.4223 |
0.357 |
|
| 2006 |
Grouix B, Julien N, Lagraoui M, Morin M, Krosl G, Roy D, Penney C, Gagnon L. PBI-1402: A Low Molecular Weight Synthetic Hematopoietic Growth Stimulant. Blood. 108: 4222-4222. DOI: 10.1182/Blood.V108.11.4222.4222 |
0.396 |
|
| 2006 |
Morin M, Krosl G, Lagraoui M, Grouix B, Penney C, Gagnon L, Roy D. Oral Administration of PBI-1402 Significantly Reduces Erythropenia and Accelerates Peripheral Blood Recovery in Myeloablated Mice Post Transplantation. Blood. 108: 3201-3201. DOI: 10.1182/Blood.V108.11.3201.3201 |
0.447 |
|
| 2006 |
Beauchemin S, Krosl G, Beslu N, Krosl J, Sauvageau G, Roy D. Ectopic Expression of Mutated HOXB4 Proteins with Increased Intracellular Stability Affects Both Long and Short Term Hematopoietic Reconstitution. Blood. 108: 3183-3183. DOI: 10.1182/Blood.V108.11.3183.3183 |
0.42 |
|
| 2006 |
Roy D, Cohen S, Busque L, Fish D, Kiss T, Lachance S, Sauvageau G, Caudrelier P, Roy J. Phase I Clinical Study of Donor Lymphocyte Infusion Depleted of Alloreactive T Cells after Haplotype Mismatched Myeloablative Stem Cell Transplantation To Limit Infections and Malignant Relapse without Causing GVHD. Blood. 108: 309-309. DOI: 10.1182/Blood.V108.11.309.309 |
0.557 |
|
| 2006 |
Santhanam R, Neviani P, Eiring A, Oaks J, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Marcucci G, Gambacorti C, Roy D, Caligiuri MA, Bloomfield CD, Chen C, et al. FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph1 ALL Patients. Blood. 108: 288-288. DOI: 10.1182/Blood.V108.11.288.288 |
0.457 |
|
| 2006 |
Chang J, Santhanam R, Briercheck E, Eiring A, Trotta R, Notari M, Roy D, Caligiuri MA, Perrotti D. Molecular and Pharmacologic Suppression of MAPK Activity Rescues Differentiation of BCR/ABL+ Myeloid Progenitors by Releasing C/EBPa from the Inhibitory Effect of hnRNP E2. Blood. 108: 2240-2240. DOI: 10.1182/Blood.V108.11.2240.2240 |
0.329 |
|
| 2005 |
Sidi Boumédine R, Roy DC. Elimination of alloreactive T cells using photodynamic therapy Cytotherapy. 7: 134-143. PMID 16040392 DOI: 10.1080/14653240510027109 |
0.369 |
|
| 2005 |
Levesque A, Savard A, Roy D, Foss F, Scotto C. Control of Cell Death Levels Using Th9402-Based PDT Treatment on Fresh PBMC, and Potential Application to Patients with cGvHD. Blood. 106: 5258-5258. DOI: 10.1182/Blood.V106.11.5258.5258 |
0.365 |
|
| 2005 |
Allan D, Dubé P, Roy J, Roy D. Mobilization of Endothelial Progenitor Cells in Autologous and Allogeneic Peripheral Blood Stem Cell Grafts. Blood. 106: 4231-4231. DOI: 10.1182/Blood.V106.11.4231.4231 |
0.471 |
|
| 2005 |
Krosl G, Giard M, Krosl J, Beauchemin S, Humphries K, Sauvageau G, Roy DC. Ex Vivo Expansion of Human SCID-Repopulating Cells Using Recombinant TAT-HOXB4 Protein. Blood. 106: 3159-3159. DOI: 10.1182/Blood.V106.11.3159.3159 |
0.38 |
|
| 2005 |
Rioux-Masse B, Roy J, Belanger R, Roy D, Busque L, Fish D, Sauvageau G, Kiss T, Cohen S. Autologous Bone Marrow Transplant after Failed Peripheral Blood Stem Cell Mobilization Does Not Adversely Affect Engraftment or Transplant Related Toxicity. Blood. 106: 2736-2736. DOI: 10.1182/Blood.V106.11.2736.2736 |
0.371 |
|
| 2005 |
Allan D, Belanger R, Busque L, Fish D, Kassis J, Roy J, Perreault C, Roy D. A Phase I Study with Long-Term Follow-Up of Autologous Stem Cell Transplantation Using Photodynamic Treatment of Marrow Grafts for Relapsed/Refractory Acute Leukemia. Blood. 106: 2201-2201. DOI: 10.1182/Blood.V106.11.2201.2201 |
0.53 |
|
| 2005 |
Sidi Boumedine R, Krosl G, Vaillancourt M, Perreault C, Roy D. Elimination of alloreactive T lymphocytes using photodynamic therapy prevents the development of GVHD and promotes B and T cell reconstitution after MHC-mismatched transplantation Biology of Blood and Marrow Transplantation. 11: 57-58. DOI: 10.1016/J.Bbmt.2004.12.172 |
0.303 |
|
| 2004 |
Levesque A, Savard A, Roy D, Foss F, Scotto C. Potential TH9402-Based ECP Treatment for cGvHD Patients. Blood. 104: 5119-5119. DOI: 10.1182/Blood.V104.11.5119.5119 |
0.521 |
|
| 2004 |
Boumedine RS, Krosl G, Vaillancourt M, Perreault C, Roy D. Specific Elimination of Alloreactive T Lymphocytes Using Photodynamic Therapy Prevents GVHD and Enables Rapid Immune Reconstitution. Blood. 104: 4987-4987. DOI: 10.1182/Blood.V104.11.4987.4987 |
0.495 |
|
| 2004 |
Guimond M, Boumedine RS, Perreault C, Roy D. Defective Production of Myeloid Dendritic Cells Results from Skewing of Chronic Myelogenous Leukemia Progenitors. Blood. 104: 4700-4700. DOI: 10.1182/Blood.V104.11.4700.4700 |
0.4 |
|
| 2004 |
Krosl G, Dube P, Dallaire N, Vaillancourt M, Roy D. Preferential Induction of B Cell Apoptosis Using Photodynamic Therapy. Blood. 104: 4643-4643. DOI: 10.1182/Blood.V104.11.4643.4643 |
0.4 |
|
| 2004 |
Krosl G, Giard M, Krosl J, Humphries RK, Sauvageau G, Roy D. Recombinant TAT-HOXB4 Protein Promotes Ex Vivo Expansion of Primitive Human Hematopoietic Cells. Blood. 104: 2855-2855. DOI: 10.1182/Blood.V104.11.2855.2855 |
0.434 |
|
| 2003 |
Poulin JF, Sylvestre M, Champagne P, Dion ML, Kettaf N, Dumont A, Lainesse M, Fontaine P, Roy DC, Perreault C, Sékaly RP, Cheynier R. Evidence for adequate thymic function but impaired naive T-cell survival following allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease. Blood. 102: 4600-7. PMID 12933579 DOI: 10.1182/Blood-2003-05-1428 |
0.506 |
|
| 2002 |
Mayotte N, Roy DC, Yao J, Kroon E, Sauvageau G. Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system. Blood. 100: 4177-84. PMID 12393433 DOI: 10.1182/Blood-2002-04-1244 |
0.432 |
|
| 2001 |
Le Blanc R, Montminy-Métivier S, Bélanger R, Busque L, Fish D, Roy DC, Kassis J, Boileau J, Lavallée R, Bélanger D, Letendre F, Hébert J, Sauvageau G, Perreault C, Roy J. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplantation. 28: 841-8. PMID 11781644 DOI: 10.1038/Sj.Bmt.1703253 |
0.31 |
|
| 2001 |
Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy DC, Perreault C. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease Nature Medicine. 7: 789-794. PMID 11433342 DOI: 10.1038/89907 |
0.409 |
|
| 2000 |
Guimond M, Busque L, Baron C, Bonny Y, Bélanger R, Mattioli J, Perreault C, Roy DC. Relapse after bone marrow transplantation: evidence for distinct immunological mechanisms between adult and paediatric populations. British Journal of Haematology. 109: 130-7. PMID 10848792 DOI: 10.1046/J.1365-2141.2000.01961.X |
0.414 |
|
| 1999 |
Brochu S, Rioux-Massé B, Roy J, Roy DC, Perreault C. Massive activation-induced cell death of alloreactive T cells with apoptosis of bystander postthymic T cells prevents immune reconstitution in mice with graft-versus-host disease Blood. 94: 390-400. PMID 10397705 DOI: 10.1182/Blood.V94.2.390 |
0.469 |
|
| 1999 |
Dulude G, Roy DC, Perreault C. The effect of graft-versus-host disease on T cell production and homeostasis. The Journal of Experimental Medicine. 189: 1329-42. PMID 10209049 DOI: 10.1084/Jem.189.8.1329 |
0.397 |
|
| 1998 |
Perreault C, Roy DC, Fortin C. Immunodominant minor histocompatibility antigens: The major ones Immunology Today. 19: 69-74. PMID 9509761 DOI: 10.1016/S0167-5699(97)01185-7 |
0.313 |
|
| 1998 |
Léonard BM, Hétu F, Busque L, Gyger M, Bélanger R, Perreault C, Roy DC. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources. Blood. 91: 331-9. PMID 9414302 DOI: 10.1182/Blood.V91.1.331.331_331_339 |
0.472 |
|
| 1996 |
Perreault C, Jutras J, Roy DC, Filep JG, Brochu S. Identification of an immunodominant mouse minor histocompatibility antigen (MiHA): T cell response to a single dominant MiHA causes graft- versus-host disease Journal of Clinical Investigation. 98: 622-628. PMID 8698852 DOI: 10.1172/Jci118832 |
0.305 |
|
| 1996 |
Lachapelle MH, Hemmings R, Roy DC, Falcone T, Miron P. Flow cytometric evaluation of leukocyte subpopulations in the follicular fluids of infertile patients Fertility and Sterility. 65: 1135-1140. PMID 8641486 DOI: 10.1016/S0015-0282(16)58327-7 |
0.347 |
|
| 1995 |
Pichert G, Roy DC, Gonin R, Alyea EP, Bélanger R, Gyger M, Perreault C, Bonny Y, Lerra I, Murray C, Soiffer RJ, Ritz J. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia Journal of Clinical Oncology. 13: 1704-1713. PMID 7602361 DOI: 10.1200/Jco.1995.13.7.1704 |
0.399 |
|
| 1994 |
Pichert G, Alyea E, Soiffer R, Roy D, Ritz J. Persistence Of Myeloid Progenitor Cells Expressing Bcr-Abl Mrna After Allogeneic Bone Marrow Transplantation For Chronic Myelogenous Leukemia Blood. 84: 2109-2114. DOI: 10.1182/Blood.V84.7.2109.2109 |
0.434 |
|
| 1993 |
Von Bueltzingsloewen A, Belanger R, Perreault C, Bonny Y, Roy DC, Boileau J, Kassis J, Lavallee R, Lacombe M, Gyger M. Allogeneic bone marrow transplantation following busulfan-cyclophosphamide with or without etoposide conditioning regimen for patients with acute lymphoblastic leukaemia British Journal of Haematology. 85: 706-713. PMID 7918033 DOI: 10.1111/J.1365-2141.1993.Tb03212.X |
0.412 |
|
| 1993 |
von Bueltzingsloewen A, Belanger R, Perreault C, Bonny Y, Roy D, Lalonde Y, Boileau J, Kassis J, Lavallee R, Lacombe M. Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies Blood. 81: 849-855. DOI: 10.1182/Blood.V81.3.849.Bloodjournal813849 |
0.44 |
|
| 1992 |
Gyger M, D'Angelo G, Belanger R, Forest L, Lussier P, Busque L, Perreault C, Boileau J, Bonny Y, Lavallee R, Lacombe M, Roy DC. Cytogenetic characterization of primary refractory anemia American Journal of Hematology. 41: 241-248. PMID 1288285 DOI: 10.1002/Ajh.2830410404 |
0.331 |
|
| 1991 |
Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. The New England Journal of Medicine. 325: 1525-33. PMID 1944436 DOI: 10.1056/NEJM199111283252201 |
0.311 |
|
| 1991 |
Roy D, Griffin J, Belvin M, Blattler W, Lambert J, Ritz J. Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Blood. 77: 2404-2412. DOI: 10.1182/Blood.V77.11.2404.2404 |
0.406 |
|
| 1990 |
Roy DC, Tantravahi R, Murray C, Dear K, Gorgone B, Anderson KC, Freedman AS, Nadler LM, Ritz J. Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. Blood. 75: 296-304. DOI: 10.1182/Blood.V75.1.296.Bloodjournal751296 |
0.459 |
|
| Show low-probability matches. |